TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2025
0mins
Source: Newsfilter
Patient Response to TCB008: The first patient in Cohort B of a clinical trial for TC BioPharm's TCB008 achieved complete molecular remission after receiving two doses of gamma delta T-cells, demonstrating the potential effectiveness of this therapy in treating blood cancers.
Company's Vision and Future Potential: TC BioPharm aims to develop innovative cell therapies that target malignant cells, with TCB008 potentially serving as a key treatment option for patients post-remission, enhancing survival rates and improving long-term outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
